Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 3Adrenocortical Adenoma 2Thyroid Nodule 1Thyroid Neoplasms 1Pancreatic Neuroendocrine Tumors, WHO Grade I-II 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Hyperaldosteronism 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1Adrenal Gland Neoplasms 1

Interventions

Paclitaxel 4fosbretabulin 3Radiotherapy 3selpercatinib 2Filgrastim 2Everolimus 2Doxorubicin 2Cisplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1sargramostim 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1mercaptoundecahydrododecaborate 1gallium Ga 68 dotatate 1fostamatinib 1entrectinib 1combretastatin 1alectinib 1aldesleukin 1Triiodothyronine 1Thyrotropin Alfa 1Thyrotropin 1Thalidomide 1Tamoxifen 1Semaxinib 1Rosiglitazone 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Radiofrequency Ablation × Endocrine × Clear all
NCT00103155 2013-09-20

Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer

National Cancer Institute (NCI)

Phase 1 Unknown
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡